Results 81 to 90 of about 16,411 (192)

Fully Synthetic Non‐Carbohydrate Heparin Mimetics—Perspectives for Therapeutic Anticoagulation and Beyond?

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
Fully synthetic sulfated non‐carbohydrate polymers for structurally mimicking the polysaccharide glycosaminoglycan heparin in its anticoagulant activities with further prospects to pleiotropic effects in oncology and in antiviral approaches. ABSTRACT Heparin is one of the oldest drugs on the market.
Katrin Nekipelov, Vito Ferro, Gerd Bendas   +2 more
wiley   +1 more source

Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. [PDF]

PLoS ONE, 2014
Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored.Medline, Embase and Web of Science were searched to March 8, 2014 for prospective ...
Shuang Li, Baoxin Liu, Dachun Xu, Yawei Xu   +3 more
doaj   +1 more source

Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial). [PDF]

, 2017
In the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) study (NCT 02072434), edoxaban was compared with enoxaparin-warfarin in 2,199 patients undergoing electrical cardioversion of nonvalvular ...
Al-Saady, N, Goette, A, Jin, J, Lip, GYH, Melino, M, Sun, M, Winters, SM, Zamoryakhin, D   +7 more
core   +2 more sources

Use of andexanet alfa: A British Society for Haematology position statement

British Journal of Haematology, EarlyView.
Richard J. Buka, Deepa J. Arachchillage, Catherine N. Bagot, Gary Benson, Charlotte A. Bradbury, Nicola Curry, Beverley J. Hunt, David J. Sutton, Mari R. Thomas, John Paul Westwood, Karen Breen   +10 more
wiley   +1 more source

Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism

Thrombosis Journal
Background Edoxaban, a direct oral anticoagulant (DOAC), is a first-line treatment for venous thromboembolism (VTE) and the suppression of VTE recurrence.
Masashi Yoshida, Kentaro Ejiri, Naoaki Matsuo, Takanori Naito, Kazuhiro Kuroda, Koji Tokioka, Kunihiko Hatanaka, Ryohei Fujimoto, Hidenaru Yamaoka, Yutaka Kajikawa, Kazuki Suruga, Hiroki Sugiyama, Tsuyoshi Miyaji, Yoshimasa Morimoto, Nobuhiro Okamura, Toshihiro Sarashina, Satoshi Akagi, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Shinsuke Yuasa   +20 more
doaj   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, Volume 92, Issue 4, Page 1177-1185, April 2026.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source

Clinical considerations on the posology of direct oral anticoagulants [PDF]

, 2016
Los anticoagulantes dicumarínicos han demostrado su eficacia en pacientes con fibrilación auricular no valvular. Sin embargo, presentan desventajas como la necesidad de ajustar la dosis y la interacción con fármacos y alimentos.
Avendaño Solá, C., González Juanatey, J.R., Peñataro Sáez, J.   +2 more
core   +2 more sources

Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer

Cancer Medicine, Volume 15, Issue 4, April 2026.
Compared with DOACs, LMWH expressed a lower risk of recurrent VTE in GI cancer patients. However, DOAC presented with a lower intracranial hemorrhage risk but a higher GI bleeding risk. ABSTRACT Background Direct oral anticoagulants (DOACs) have demonstrated non‐inferiority to low‐molecular‐weight heparin (LMWH) for preventing recurrent venous ...
Wei‐Ting Chang, Mei‐Chuan Lee, Hui‐Wen Lin, Sheng‐Hsiang Lin, Yi‐Heng Li   +4 more
wiley   +1 more source

Determination of Edoxaban in Bulk and in Tablet Dosage Form by Stability Indicating High-Performance Liquid Chromatography

Pharmaceutical Sciences, 2016
Background: Edoxaban is an orally active direct factor Xa inhibitor. The aim of the present study was to develop a stability indicating HPLC method for the quantification of edoxaban in bulk and in tablet dosage form. Methods: Edoxaban was separated on
Pasam Satyanarayana Reddy , V. Shanmukha Kumar Jagarlapudi, Chandra Bala Sekaran
doaj   +1 more source

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source